TG Therapeutics (TGTX) Projected to Post Earnings on Monday

TG Therapeutics (TGTX) is scheduled to report Q3 2025 earnings on November 3rd, with analysts forecasting $0.24 EPS and $152.115 million in revenue. This follows a Q2 2025 earnings miss, where the company reported $0.17 EPS against a $0.32 consensus, though revenue grew 92.1% year-over-year to $141.15 million. While the stock opened up 2.2% at $34.78, a director recently sold over $672,000 worth of shares, reducing their stake by 18.15%; however, several institutional investors significantly increased their holdings in TGTX during the first and second quarters, bringing institutional ownership to 58.58%.

Analysis

TG Therapeutics (TGTX) is scheduled to report Q3 2025 results on November 3rd, with analysts projecting EPS of $0.24 and revenue of $152.115 million. This follows a Q2 2025 earnings miss, where the company reported $0.17 EPS against a $0.32 consensus, despite a robust 92.1% year-over-year revenue growth to $141.15 million. The firm's Q2 performance also showed a strong return on equity of 26.05% and a net margin of 13.31%.

Despite the recent earnings miss, TGTX shares opened up 2.2% at $34.78, indicating some market resilience or positive anticipation. The stock currently trades at a high P/E ratio of 94.00, reflecting growth expectations, and has a beta of 1.97, suggesting higher volatility relative to the market. Its market capitalization stands at $5.52 billion, with a healthy current ratio of 3.86 and a quick ratio of 2.96.

Institutional investors hold a significant 58.58% of TGTX, with several major funds increasing their stakes in Q1 and Q2, signaling confidence. However, a director recently sold 20,852 shares for over $672,000, reducing their ownership by 18.15%, which could be a point of concern for some investors. Analysts currently forecast $0 EPS for the current fiscal year and $1 EPS for the next fiscal year, indicating a projected return to profitability.

Key Decisions for Investors

• Monitor Q3 2025 earnings closely for analyst estimate alignment and future guidance, as recent performance has been mixed despite strong revenue growth.
• Evaluate the implications of the high P/E ratio (94.00) against the projected EPS growth for the next fiscal year ($1.00), considering the stock's high beta (1.97) for potential volatility.
• Consider the mixed signals from insider selling versus strong institutional accumulation, and assess the company's financial health indicators like ROE, net margin, and liquidity ratios.